Cardiovascular pharmacology of purines

Clinical Science

Volumn 92, Issue 1, 1997, Pages 13-24

  Rongen, Gerard A ^a   Floras, John S ^a   Lenders, Jacques W M ^b   Thien, Theo ^b   Smits, Paul ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular; Pharmacology; Purines; Sympathetic nervous system

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; ENDOTHELIUM DERIVED RELAXING FACTOR; NEUROTRANSMITTER; NORADRENALIN; PURINE; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR;

ADRENERGIC SYSTEM; CARDIOVASCULAR SYSTEM; DEGRADATION; ENDOTHELIUM; EXERCISE; FOREARM; HEART; ISCHEMIA; KIDNEY; PATHOPHYSIOLOGY; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SYMPATHETIC NERVE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; VASOSPASM;

EID: 0031028033     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0920013     Document Type: Review

References (165)

1. Drury AN, Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol (London) 1929; 68: 213-37.
2. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 70: 761-845.
3. Burnstock G, Sneddon P. Evidence for ATP and noradrenaline as cotransmitters in sympathetic nerves. Clin Sci 1985; 68 (Suppl. 10): 89-92s.
4. Meghji P. Storage, release, uptake, and inactivation of purines. Drug Dev Res 1993; 28: 214-19.
5. Meghji P, Rubio R, Berne RM. Intracellular adenosine formation and its carrier-mediated release in cultured embryonic chick heart cells. Life Sci 1988; 43: 1851-9.
6. Borst MM, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res 1991; 68: 797-806.
7. Kroll K, Kelm MK, Burrig KF, Schrader J. Transendothelial transport and metabolism of adenosine and inosine in the intact rat aorta. Circ Res 1989; 64: 1147-57.
8. Kitakaze M, Hori M, Morioka T, et al. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity. J Clin Invest 1994; 93: 2197-205.
9. Born GV, Kratzer MA. Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol (London) 1984; 354: 419-29.
10. Milner P, Bodin P, Loesch A, Burnstock G. Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow. Biochem Biophys Res Commun 1990; 170: 649-56.
11. Sedaa KO, Bjur RA, Shinozuka K, Westfall DP. Nerve and drug-induced release of adenine nucleosides and nucleotides from rabbit aorta. J Pharmacol Exp Ther 1990; 252: 1060-7.
12. Yang S, Cheek DJ, Westfall DP, Buxton IL. Purinergic axis in cardiac blood vessels. Agonist-mediated release of ATP from cardiac endothelial cells. Circ Res 1994; 74: 401-7.
13. Van Belle H. Uptake and deamination of adenosine by blood. Species differences, effect of pH, ions, temperature and metabolic inhibitors. Biochim Biophys Acta 1969; 192: 124-32.
14. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J 1986; 233: 309-19.
15. Burnstock G. Classification and characterization of purinoceptors. In: Jacobson KA, Daly JW, Manganiello V, eds. Purines in cellular signaling - targets for new drugs. New York: Springer-Verlag, 1990: 241-53.
16. 2 receptors: structure-function relationships. Med Res Rev 1992; 12: 423-71.
17. Gerwins P, Fredholm BB. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line. J Biol Chem 1992; 267: 16081-7.
18. 1-selective adenosine agonist in porcine coronary artery - involvement of potassium channels. J Pharmacol Exp Ther 1992; 260: 437-43.
19. 1-receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990; 259: H820-6.
20. 3 adenosine receptor. Proc Natl Acad Sci USA 1992; 89: 7432-6.
21. 3 receptor-mediated hypotension in the rat. Br J Pharmacol 1995; 115: 945-52.
22. Armstrong S, Ganote CE. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A3 receptor involvement. Cardiovasc Res 1994; 28: 1049-56.
23. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 1985; 16: 433-40.
24. 2x-receptor, in rabbit basilar artery: a receptor for pyrimidine nucleotides and a receptor for purine nucleotides. Naunyn Schmiedeberg's Arch Pharmacol 1990; 341: 538-46.
25. Mannix RJ, Moaner T, Kelley KA, Gerritsen ME. Cellular signaling responses mediated by a novel nucleotide receptor in rabbit microvessel endothelium. Am J Physiol 1993; 265: H675-80.
26. 2y subtypes. Drug Dev Res 1994; 31: 206-19.
27. Fredholm BB, Abbrachio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143-56.
28. 2y purinoceptors in rat brain microvascular endothelial cells. Br J Pharmacol 1995; 115: 1199-203.
29. 3H]-alpha, beta-methylene ATP, a radioligand labelling P2-purinoceptors. J Auton Nerv Syst 1989; 28: 85-8.
30. Sneddon P, Burnstock G. Inhibition of excitatory junction potentials in guinea-pig vas deferens by alpha, beta-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmacol 1984; 100: 85-90.
31. Dalziel HH, Gray GA, Drummond RM, Furman BL, Sneddon P. Investigation of the selectivity of alpha, beta-methylene ATP in inhibiting vascular responses of the rat in vivo and in vitro. Br J Pharmacol 1990; 99: 820-4.
32. Stjarne L, Msghina M, Stjarne E. Individual variations in potency of alpha,beta-methylene ATP as inhibitor of the excitatory junction current in mouse vas deferens caused by sympathetic nerve stimulation. Acta Physiol Scand 1989; 137: 315-16.
33. Wilkinson GF, McKechnie K, Dainty IA, Boarder MR. P2Y purinoceptor and nucleotide receptor-induced relaxation of precontracted bovine aortic collateral artery rings; differential sensitivity to suramin and indomethacin. J Pharmacol Exp Ther 1994; 268: 881-7.
34. Bailey SJ, Hourani SMO. Effects of suramin on contractions of the guinea-pig vas deferens induced by analogues of adenosine-5′-triphosphate. Br J Pharmacol 1995; 114: 1125-32.
35. 2 purinoceptor classification. Br J Pharmacol 1994; 113: 463-70.
36. Webb TE, Simon J, Krishek BJ, et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 1993; 324: 219-25.
37. 2y purinergic receptor that couples to phospholipase C. Mol Pharmacol 1994; 46: 8-14.
38. 2a nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci USA 1994; 91: 3275-9.
39. Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature (London) 1994; 371: 519-23.
40. 2x receptor for extracellular ATP. Nature (London) 1994; 371: 516-18.
41. Cusack NJ, Hourani SM. Subtypes of P2-purinoceptors. Studies using analogues of ATP. Ann N Y Acad Sci 1990; 603: 172-81.
42. Wagner WR, Hubbell JA. ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen. Thromb Haemostasis 1992; 67: 461-7.
43. 2T purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol 1995; 115: 1110-16.
44. 2zpurinergic receptors expressed in xenopus oocytes. J Biol Chem 1994; 269: 13988-96.
45. 2z receptor of human macrophage cells. Characterization and possible physiological role. J Clin Invest 1995; 95: 1207-16.
46. 2 purinergic receptors for diadenosine polyphosphates in the nervous system. Gen Pharmacol 1994; 26: 229-35.
47. 5A and α,β-methylene ATP on nonadrenergic, noncholinergic neurogenic excitation in the guinea-pig vas deferens. Br J Pharmacol 1988; 94: 699-706.
48. Cristalli G, Vittori S, Thompson RD, et al. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedeberg's Arch Pharmacol 1994; 349: 644-50.
49. Vuorinen P, Porsti I, Metsaketela T, Manninen V, Vapaatalo H, Laustiola KE. Endothelium-dependent and endothelium-independent effects of exogenous ATP, adenosine, GTP and guanosine on vascular tone and cyclic nucleotide accumulation of rat mesenteric artery. Br J Pharmacol 1992; 105: 279-84.
50. 2y-purinoceptors in the isolated perfused rat heart. Eur J Pharmacol 1987; 136: 49-54.
51. Martin GN, Thorn SAM, Sever PS. The effects of adenosine triphosphate (ATP) and related purines on human isolated subcutaneous and omental resistance arteries. Br J Pharmacol 1991; 102: 645-50.
52. Pearson J, Carleton J, Gordon J. Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem J 1980; 190: 421-9.
53. 2, and adenine nucleotides. J Clin Invest 1986; 78: 539-44.
54. Warland JJ, Burnstock G. Effects of reserpine and 6-hydroxydopamine on the adrenergic and purinergic components of sympathetic nerve responses of the rabbit saphenous artery. Br J Pharmacol 1987; 92: 871-80.
55. Ralevic V, Burnstock G. Postjunctional synergism of noradrenaline and adenosine 5′-triphosphate in the mesenteric arterial bed of the rat. Eur J Pharmacol 1990; 175: 291-9.
56. Corr L, Burnstock G. Vasodilator response of coronary smooth muscle to the sympathetic co-transmitters noradrenaline and adenosine 5′-triphosphate. Br J Pharmacol 1991; 104: 337-42.
57. Mathieson JJ, Burnstock G. Purine-mediated relaxation and constriction of isolated rabbit mesenteric artery are not endothelium-dependent. Eur J Pharmacol 1985; 118: 221-9.
58. Rongen GA, Smits P, Thien T. Characterization of ATP-induced vasodilation in the human forearm vascular bed. Circulation 1994; 90: 1891-8.
59. 2-purinoceptors. Br J Pharmacol 1991; 103: 1103-7.
60. Neely CF, Haile DM, Cahill BE, Kadowitz PJ. Adenosine and ATP produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. J Pharmacol Exp Ther 1991; 258: 753-61.
61. Utterback DB, Staples ED, White SE, Hill JA, Belardinelli L. Basis for the selective reduction of pulmonary vascular resistance in humans during infusion of adenosine. J Appl Physiol 1994; 76: 724-30.
62. Sabouni MH, Ramagopal MV, Mustafa SJ. Relaxation by adenosine and its analogues of potassium-contracted human coronary arteries. Naunyn Schmiedeberg's Arch Pharmacol 1990; 341: 388-90.
63. Parent R, Pare R, Lavallee M. Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs. Am J Physiol 1992; 262: H10-16.
64. 2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun 1994; 199: 905-10.
65. Headrick JP, Northington FJ, Hynes MR, Matherne GP, Berne RM. Relative responses to luminal and adventitial adenosine in perfused arteries. Am J Physiol 1992; 263: H1437-46.
66. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82: 1595-606.
67. Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin Pharmacol Ther 1990; 48: 410-18.
68. Johnston DL, Daley JR, Hodge DO, Hopfenspirger MR, Gibbons RJ. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologie stress testing: a comparison in 2000 patients. Mayo Clin Proc 1995; 70: 331-6.
69. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135-41.
70. 2 receptor mediated coronary vasodilatation in the dog. Cardiovasc Res 1994; 28: 906-11.
71. Westfall DP, Shinozuka K, Forsyth KM, Bjur RA. Presynaptic purine receptors. Ann N Y Acad Sci 1990; 604: 130-5.
72. 2-purinoceptor-mediated inhibition of noradrenaline release in rat brain cortex. Br J Pharmacol 1994; 113: 815-22.
73. Rongen GA, Lenders JWM, Lambrou G, et al. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension 1996; 27: 933-8.
74. Richardson PJ, Brown SJ, Bailyes EM, Luzio JP. Ectoenzymes control adenosine modulation of immunoisolated cholinergic synapses. Nature (London) 1987; 327: 232-4.
75. Ragazzi E, Wu S-N, Shryock J, Belardinelli L. Electrophysiobgical and receptor binding studies to assess activation of the cardiac adenosine receptor by adenine nucleotides. Circ Res 1991; 68: 1035-44.
76. Pelleg A, Belhassen B, Ilia R, Laniado S. Comparative electrophysiologic effects of adenosine triphosphate and adenosine in the canine heart: influence of atropine, propranolol, vagotomy, dipyridamole and aminophylline. Am J Cardiol 1985; 55: 571-6.
77. Belardinelli L, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32: 73-97.
78. Shen W-K, Kurachi Y. Mechanisms of adenosine-mediated actions on cellular and clinical cardiac electrophysiology. Mayo Clin Proc 1995; 70: 274-91.
79. Belardinelli L, Pelleg A. Cardiac electrophysiology and pharmacology of adenosine. J Cardiovasc Electrophysiol 1990; 1: 327-39.
80. 1 adenosine receptor-mediated effects in humans. Circulation 1996; 93: 1871-6.
81. DiMarco JP, Sellers TD, Berne RM, West GA, Belardinelli L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68: 1254-63.
82. Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992; 92: 655-64.
83. Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res 1987; 61: 779-86.
84. Wainwright CL, Parratt JR. An antiarrhythmic effect of adenosine during myocardial ischemia and reperfusion. Eur J Pharmacol 1988; 146: 183-94.
85. Lerman B. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation 1993; 87: 382-90.
86. Alvarez JL, Mongo K, Scamps F, Vassort G. Effects of purinergic stimulation on the Ca current in single frog cardiac cells. Pflugers Arch 1990; 416: 189-95.
87. Scamps F, Vassort G. Mechanism of extracellular ATP-induced depolarization in rat isolated ventricular cardiomyocytes. Pflugers Arch 1990; 417: 309-16.
88. Scamps F, Legssyer A, Mayoux E, Vassort G. The mechanism of positive inotropy induced by adenosine triphosphate in rat heart. Circ Res 1990; 67: 1007-16.
89. Thompson CI, Spielman WS. Renal hemodynamic effects of exogenously administered adenosine and polyadenylic acid. Am J Physiol 1992; 263: F816-23.
90. Weihprecht H, Lorenz JN, Briggs JP, Schnermann J. Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am J Physiol 1994; 266: F227-39.
91. Okumura M, Miura K, Yamashita Y, Yukimura T, Yamamoto K. Role of endothelium-derived relaxing factor in the in vivo renal vascular action of adenosine in dogs. J Pharmacol Exp Ther 1992; 260: 1262-7.
92. Arend LJ, Haramati A, Thompson CI, Spielman WS. Adenosine-induced decrease in renin release: dissociation from hemodynamic effects. Am J Physiol 1984; 247: F447-52.
93. Kurtz A, Delia Bruna R, Pfeilschifter J, Bauer C. Role of cGMP as second messenger of adenosine in the inhibition of renin release. Kidney Int 1988; 33: 798-803.
94. Fisher JW, Nakashima J. The role of hypoxia in renal production of erythropoietin. Cancer 1992; 70: 928-39.
95. Inscho EW, Ohishi K, Navar LG. Effects of ATP on pre- and postglomerular juxtamedullary microvasculature. Am J Physiol 1992; 263: F886-93.
96. Inscho EW, Mitchell KD, Navar LG. Extracellular ATP in the regulation of renal microvascular function. FASEB J 1994; 8: 319-28.
97. Pfeilschifter J. Comparison of extracellular ATP and UTP signalling in rat renal mesangial cells. No indications for the involvement of separate purino- and pyrimidino-ceptors. Biochem J 1990; 272: 469-72.
98. Katholi RE, Hageman GR, Whidow PL, Woods WT. Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension 1983; 5: 1149-54.
99. Dibner-Dunlap ME, Kinugawa T, Thames MD. Activation of cardiac sympathetic afferents - effects of exogenous adenosine and adenosine analogues. Am J Physiol 1993; 265: H395-400.
100. Cox DA, Vita JA, Treasure CB, Fish RD, Selwyn AP, Ganz P. Reflex increase in blood pressure during intracoronary administration of adenosine in man. J Clin Invest 1989; 84: 592-6.
101. Costa F, Biaggioni I. Role of adenosine in the sympathetic activation produced by isometric exercise in humans. J Clin Invest 1994; 93: 1654-60.
102. Watt AH, Reid PG, Stephens MR, Routledge PA. Adenosine-induced respiratory stimulation in man depends on site of infusion. Evidence for an action on the carotid body? Br J Clin Pharmacol 1987; 23: 486-90.
103. Biaggioni I, Killian TJ, Mosqueda Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation 1991; 83: 1668-75.
104. Smits P, Boekema P, Thien T, de Abreu R, van't Laar A. Evidence for an antagonism between caffeine and adenosine in the cardiovascular system in man. J Cardiovasc Pharmacol 1987; 10: 136-43.
105. Edlund A, Sollevi A, Linde B. Haemodynamic and metabolic effects of infused adenosine in man. Clin Sci 1990; 79: 131-8.
106. Conradson TB, Clarke B, Dixon CM, Dalton RN, Barnes PJ. Effects of adenosine on autonomie control of heart rate in man. Acta Physiol Scand 1987; 131: 525-31.
107. Fukunaga AF, Flacke WE, Bloor BC. Hypotensive effects of adenosine and adenosine triphosphate compared with sodium nitroprusside. Anesth Analg 1982; 61: 273-8.
108. Maxwell DL, Fuller RW, Conradson TB, et al. Contrasting effects of two xanthines, theophylline and enprofylline, on the cardio-respiratory stimulation of infused adenosine in man. Acta Physiol Scand 1987; 131: 459-65.
109. Bush A, Busst CM, Clarke B, Barnes PJ. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. Br J Clin Pharmacol 1989; 27: 165-71.
110. Smits P, Thien T, van't Laar A. Circulatory effects of coffee in relation to the pharmacokinetics of caffeine. Am J Cardiol 1985; 56: 958-63.
111. Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther 1991; 50: 529-37.
112. Sollevi A, Ostergren J, Fagrell B, Hjemdahl P. Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiol Scand 1984; 121: 165-71.
113. Rongen GA, Smits P, Ver Donck K, et al. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J Clin Invest 1995; 95: 658-68.
114. PARIS II Research Group . Persantine-Aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
115. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62: 449-61.
116. Gaspardone A, Crea F, Tomai F, et al. Muscular and cardiac adenosine-induced pain is mediated by A1 receptors. J Am Coll Cardiol 1995; 25: 251-7.
117. Crea F, Gaspardone A, Kaski JC, Davies G, Maseri A. Relation between stimulation site of cardiac afferent nerves by adenosine and distribution of cardiac pain: results of a study in patients with stable angina. J Am Coll Cardiol 1992; 20: 1498-502.
118. Bertolet BD, Belardindli L, Hill JA. Absence of adenosine-induced chest pain after total cardiac afferent denervation. Am J Cardiol 1993; 72: 483-4.
119. Thames MD, Kinugawa T, Dibner Dunlap ME. Reflex sympathoexcitation by cardiac sympathetic afferents during myocardial ischemia. Role of adenosine. Circulation 1993; 87: 1698-704.
120. Ellenbogen KA, Thames MD, DiMarco JP, Sheehan H, Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart; evidence of supersensitivity. Circulation 1990; 81: 821-8.
121. Crea F, Pupita G, Galassi AR, et al. Role of adenosine in pathogenesis of anginal pain. Circulation 1990; 81: 164-72.
122. Hendler AL, Greyson ND, Robinson MG, Freeman MR. Patients with symptomatic ischemia have larger thallium perfusion abnormalities and more adverse prognosis than patients with silent ischemia. Can J Cardiol 1992; 8: 814-18.
123. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67: 1073-8.
124. Armour JA, Huang MH, Pelleg A, Sylven C. Responsiveness of in situ canine nodose ganglion afferent neurones to epicardial mechanical or chemical stimuli. Cardiovasc Res 1994; 28: 1218-25.
125. Van Belle H, Goossens F, Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol 1987; 252: H886-93.
126. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85: 893-904.
127. Pettersen MD, Abe T, Morgan DA, Gutterman DD. Role of adenosine in postischemic dysfunction of coronary innervation. Circ Res 1995; 76: 95-101.
128. Richardt G, Waas W, Kranzhofer R, Mayer E, Schomig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 1987; 61: 117-23.
129. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21: 886-93.
130. Kitakaze M, Hori M, Sato H, et al. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res 1991; 69: 1402-8.
131. Keller MW, Geddes L, Spotnitz W, Kaul S, Duling BR. Microcirculatory dysfunction following perfusion with nyperkalemic, hypothermic, cardioplegic solutions and blood reperfusion. Effects of adenosine. Circulation 1991; 84: 2485-94.
132. Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine; infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation 1992; 86: 986-94.
133. Auchampach JA, Gross GJ. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993; 264: H1327-36.
134. Ogawa T, Miura T, Shimamoto K, Imura O. Activation of adenosine receptors before ischemia enhances tolerance against myocardial stunning in the rabbit heart. J Am Coll Cardiol 1996; 27: 225-33.
135. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
136. Yellon DM, Baxter GF, Marber MS. Angina reassessed: pain or protector? Lancet 1996; 347: 1159-62.
137. 1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85: 659-65.
138. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994; 266: H1145-52.
139. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation 1995; 92: 1546-57.
140. + currents by protein kinase C and adenosine. Circ Res 1996; 78: 443-54.
141. Kitakaze M, Hori M, Morioka T, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation 1994; 89: 1237-46.
142. Node K, Hasegawa M, Kuzuya T, Sakamoto H, Shinozaki Y, Mori H. Activation of protein kinase C reduces infarct size through augmentation of ecto-5′-nucleotidase activity in canine myocardium. Circulation 1995; 92: 1-717 [Abstract].
143. 2y agonists on adenosine transport in cultured chromaffin cells. J Neurochem 1993; 60: 613-19.
144. Woolfson RG, Patel VC, Neild GH, Yellon DM. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 1995; 91: 1545-51.
145. Weselcouch EO, Baird AJ, Sleph P, Graver GJ. Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts. Am J Physiol 1995; 268: H242-9.
146. Pang CY, Yang RZ, Zhong A, Xu N, Boyd B, Forrest CR. Acute ischaemic preconditioning protects against skeletal muscle infarction in the pig. Cardiovasc Res 1995; 29: 782-8.
147. + channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 1995; 92: 4666-70.
148. Miller LP, Hsu C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J Neurotrauma 1992; 9: S563-77.
149. Simpson RE, Oregan MH, Perkins LM, Phillis JW. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex - effects of adenosine receptor agonists and antagonists. J Neurochem 1992; 58: 1683-90.
150. Murray TF, Zhang G, Franklin PH. Manipulation of endogenous adenosine affects seizure susceptibility. Drug Dev Res 1993; 28: 410-15.
151. Toombs CF, Wiltse AL, Shebuski RJ. Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium; implication of norepinephrine release in the preconditioning effect. Circulation 1993; 88: 2351-8.
152. Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DA, Li RK. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia. Cardiovasc Res 1994; 28: 1285-91.
153. Seyfarth M, Richardt G, Mizsnyak A, Kurz T, Schomig A. Transient ischemia reduces norepinephrine release during sustained ischemia. Neural preconditioning in isolated rat heart. Circ Res 1996; 78: 573-80.
154. Laxson DD, Homans DC, Bache RJ. Inhibition of adenosine-mediated coronary vasodilation exacerbates myocardial ischemia during exercise. Am J Physiol 1993; 265: H1471-7.
155. Barbour MM, Garber CE, Ahlberg AW, Cloutier DJ, McClellan JR, Heller GV. Effects of intravenous theophylline on exercise-induced myocardial ischemia: II. A concentration-dependent phenomenon. J Am Coll Cardiol 1993; 22: 1155-8.
156. Gaspardone A, Crea F, Iamele M, et al. Bamiphylline improves exercise-induced myocardial ischemia through a novel mechanism of action. Circulation 1993; 88: 502-5.
157. Minamino T, Kitakaze M, Mozioka T, et al. Bidirectional effects of aminophylline on myocardial ischemia. Circulation 1995; 92: 1254-60.
158. Crea F, Gaspardone A, Araujo L, et al. Effects of aminophylline on cardiac function and regional myocardial perfusion; implications regarding its antiischemic action. Am Heart J 1994; 127: 817-24.
159. Bugge E, Ytrehus K. Ischaemic preconditioning is protein kinase C dependent but not through stimulation of a adrenergic or adenosine receptors in the isolated rat heart. Cardiovasc Res 1995; 29: 401-6.
160. Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension 1991; 17: 117-30.
161. Gouyon J-B, Guignard J-P. Theophylline prevents the hypoxemia-induced renal hypodynamic changes in rabbits. Kidney Int 1988; 33: 1078-83.
162. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195: 17-22.
163. Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991; 31: 342-7.
164. Van Belle H, Janssen PAJ. Comparative pharmacology of nucleoside transport inhibitors. Nucleosides Nucleotides 1991; 10: 975-82.
165. Amoah-Apraku B. Xu J, Lu JY, Pelleg A, Bruns RF, Belardinelli L. Selective potentiation by an A(1) adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J Pharmacol Exp Ther 1993; 266: 611-17.